SG11201603506PA - Treatment of damaged nerve with pten inhibitor - Google Patents
Treatment of damaged nerve with pten inhibitorInfo
- Publication number
- SG11201603506PA SG11201603506PA SG11201603506PA SG11201603506PA SG11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- damaged nerve
- pten inhibitor
- pten
- inhibitor
- Prior art date
Links
- 229940123940 PTEN inhibitor Drugs 0.000 title 1
- 210000005036 nerve Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899795P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/063900 WO2015066701A1 (en) | 2013-11-04 | 2014-11-04 | Treatment of damaged nerve with pten inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603506PA true SG11201603506PA (en) | 2016-05-30 |
Family
ID=53005300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603506PA SG11201603506PA (en) | 2013-11-04 | 2014-11-04 | Treatment of damaged nerve with pten inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10584153B2 (en) |
| EP (1) | EP3066116B1 (en) |
| JP (1) | JP6483115B2 (en) |
| KR (2) | KR102086886B1 (en) |
| CN (1) | CN105873942B (en) |
| AU (1) | AU2014341899B2 (en) |
| CA (1) | CA2929483C (en) |
| SG (1) | SG11201603506PA (en) |
| WO (1) | WO2015066701A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110049994B (en) * | 2016-12-08 | 2023-05-02 | 拜西欧斯(北京)生物技术有限公司 | A kind of conjugate and its application |
| EP3773506A4 (en) * | 2018-03-29 | 2021-12-22 | Technion Research & Development Foundation Limited | BUBBLES WITH A PTEN INHIBITOR AND USES |
| KR20200080554A (en) * | 2018-12-27 | 2020-07-07 | 가톨릭관동대학교산학협력단 | Composition comprising ebp50 for peripheral nerve repair |
| JP2024504869A (en) * | 2020-12-04 | 2024-02-01 | コロン ティッシュジーン,インク | Treatment of spinal cord injury with PTEN inhibitors |
| IL316553A (en) | 2022-05-15 | 2024-12-01 | Nurexone Biologic Ltd | Anti-pten rna interference oligonucleotides and uses thereof |
| CN116769037B (en) * | 2022-09-14 | 2024-09-10 | 嘟乐士生物制药(河北)股份有限公司 | Anti-aging composition containing collagen and application thereof in premature senility |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110189308A1 (en) * | 2008-03-17 | 2011-08-04 | Asa Abeliovich | Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway |
| CA2724199C (en) * | 2008-06-06 | 2016-07-26 | Children's Medical Center Corporation | Promoting axon regeneration in the adult cns through control of protein translation |
| JP5517078B2 (en) * | 2009-04-09 | 2014-06-11 | 国立大学法人 宮崎大学 | PTEN phosphorylation inhibitor or dephosphorylation agent |
| KR20100121710A (en) * | 2009-04-30 | 2010-11-18 | 한국과학기술원 | Method for prevention and treatment of retinal degeneration comprising activity regulation and administration of pten |
| EP2488637B1 (en) * | 2009-10-16 | 2015-12-23 | The University Of British Columbia | Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods |
| CA2854225A1 (en) * | 2011-11-01 | 2013-05-10 | Children's Medical Center Corporation | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
-
2014
- 2014-11-04 CN CN201480072117.9A patent/CN105873942B/en active Active
- 2014-11-04 JP JP2016528048A patent/JP6483115B2/en active Active
- 2014-11-04 EP EP14858772.8A patent/EP3066116B1/en active Active
- 2014-11-04 AU AU2014341899A patent/AU2014341899B2/en active Active
- 2014-11-04 KR KR1020167014896A patent/KR102086886B1/en active Active
- 2014-11-04 WO PCT/US2014/063900 patent/WO2015066701A1/en not_active Ceased
- 2014-11-04 SG SG11201603506PA patent/SG11201603506PA/en unknown
- 2014-11-04 KR KR1020187021320A patent/KR102405411B1/en active Active
- 2014-11-04 CA CA2929483A patent/CA2929483C/en active Active
-
2016
- 2016-04-29 US US15/142,324 patent/US10584153B2/en active Active
-
2020
- 2020-03-05 US US16/810,667 patent/US20200270319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105873942B (en) | 2020-12-29 |
| JP2017500283A (en) | 2017-01-05 |
| KR102405411B1 (en) | 2022-06-08 |
| JP6483115B2 (en) | 2019-03-13 |
| WO2015066701A1 (en) | 2015-05-07 |
| AU2014341899A1 (en) | 2016-06-16 |
| CN105873942A (en) | 2016-08-17 |
| EP3066116B1 (en) | 2021-12-01 |
| EP3066116A1 (en) | 2016-09-14 |
| US20160340396A1 (en) | 2016-11-24 |
| KR20160091347A (en) | 2016-08-02 |
| US20200270319A1 (en) | 2020-08-27 |
| AU2014341899B2 (en) | 2018-12-13 |
| CA2929483A1 (en) | 2015-05-07 |
| CA2929483C (en) | 2021-11-23 |
| EP3066116A4 (en) | 2017-04-26 |
| KR102086886B1 (en) | 2020-03-10 |
| US10584153B2 (en) | 2020-03-10 |
| KR20180095085A (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201505956B (en) | Methods of treating melanoma | |
| SG11201601412XA (en) | Compositions and methods for the treatment of presbyopia | |
| GB201317005D0 (en) | Composition and methods of treatment | |
| IL252547A0 (en) | Treatment of multiple sclerosis with laquinimod | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201508515B (en) | Treatment of coal | |
| IL240014A0 (en) | Treatment of multiple sclerosis with laquinimod | |
| SG11201603506PA (en) | Treatment of damaged nerve with pten inhibitor | |
| PL2968478T3 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| IL240763A0 (en) | Halogenopyrazoles as inhibitors of therombin | |
| IL241096B (en) | Method of treatment | |
| GB201607581D0 (en) | Treatment of cancer | |
| ZA201601626B (en) | Treatment of gases | |
| GB2525530B (en) | Treatment of hard surfaces | |
| AU2013901359A0 (en) | Methods of Treatment | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201320653D0 (en) | Treatment of plants | |
| GB201306411D0 (en) | Treatment of inflammatory conditions | |
| AU2013902652A0 (en) | Treatment of minerals | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| AU2013904712A0 (en) | Method of Treatment | |
| AU2013904170A0 (en) | Method of treatment |